MedWatch

Top US business group warns of Congress failure on R&D tax perk

The CEO of Business Roundtable is concerned that an R&D tax deduction with bipartisan support is falling off the political radar, saying the absence of a tax break would limit companies’ choices.

Photo: Anna Moneymaker/AFP/Ritzau Scanpix

One of Washington’s most prominent business groups sent a warning about an impasse in Congress over a corporate tax break for research and development costs.

Business Roundtable Chief Executive Officer Joshua Bolten on Wednesday flagged concerns that reviving the deduction for R&D will fall off of Congress’s agenda later this year, despite it having bipartisan support.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs